Grifols nabs Talecris in $4B buyout deal

Spain's Grifols has struck a $4 billion deal to buy Talecris Biotherapeutics, finally delivering a premium return for the investment groups that backed the Research Triangle Park, NC-based biotech. Talecris shareholders get a mix of $19 a share in cash along with stock--a combo package that offers a 53 percent premium over Talecris' 30-day average. Grifols gets a U.S. biotech that was spun out of Bayer five years ago when Cerberus and Ampersand Ventures bought up the plasma business. For...